Gene therapy for endometrial carcinoma with the herpes simplex thymidine kinase gene

Gynecologic Oncology

Volumn 76, Issue 3, 2000, Pages 305-310

  Ugur Ural, Ali ^a   Takebe, Naoko ^b   Adhikari, Debasis ^b   Ercikan Abali, Emine ^b   Banerjee, Debabrata ^b   Barakat, Richard ^b   Bertino, Joseph R ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Endometrial carcinoma; Gene therapy

Indexed keywords

COMPLEMENTARY DNA; DIHYDROFOLATE REDUCTASE; GANCICLOVIR; GENE PRODUCT; THYMIDINE KINASE; VIRUS ENZYME;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0004728575     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5707     Document Type: Article

References (28)

1. Burke T W, Eifel P J, Muggia F M. Cancer of the uterine body. DeVita V T, Hellmann S, Rosenberg S A. Cancer Principles & Practice of Oncology. 1996;1478-1496 Lippincott-Raven, Philadelphia, New York.
2. Moolten F L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46:1986;5276-5281.
3. Moolten F L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1:1994;279-287.
4. De Clercq E. Biochemical aspects of the selective antiherpes activity of nucleoside analoges. Biochem Pharmacol. 33:1984;2159-2169.
5. Freeman S M, Abboud C N, Whartenby K A, Packman C H, Koeplin D S, Moolten F L. The bystander effect: Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1993;5274-5283.
6. Bi W L, Parysek L M, Warnick R, Stambrook P J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther. 4:1993;725-731.
7. Tong X V, Block A, Chen S H, Woo S LC, Kieback D G. Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir. Anticancer Res. 16:1996;1611-1618.
8. Rosenfield M E, Wang M, Siegal G D, Alvarez R D, Mikheeva G, Krasnykh V, Curiel D T. Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J Mol Med. 74:1996;455-462.
9. Kunishige I, Samejima Y, Shiki Y, Moriyama A, Meruelo D, Saji F, Murata Y. Suicide gene therapy for human uterine adenocarcinoma cells using herpes simplex virus thymidine kinase. Gynecol Oncol. 72:1999;16-25.
10. Kim J, Hwang E S, Kim J S, You E H, Lee S H, Lee J H. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mice. Cancer Gene Ther. 6:1999;172-178.
11. Tong X W, Kieback, Ramesh R, Freeman S M. Molecular aspects of ovarian cancer. Is gene therapy the solution. Hematol Oncol Clin North Am. 13:1999;109-133.
12. Rubin S C, Federici M G, Lloyd K O, Lewis J L, Hoskins W J. Characterization of a human endometrial carcinoma cell line producing intraperitoneal tumor growth in immunodeficient mice. Gynecol Oncol. 45:1992;273-278.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
14. Varmus H. Retroviruses. Science. 240:1988;1427-1435.
15. Boviatsis E J, Chase M, Wei M. Gene transfer into experimental brain tumors mediated by adenovirus, herpes-simplex-virus (HSV), and retrovirus vectors. Hum Gene Ther. 5:1994;183-191.
16. Moolten F L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46:1986;5276-5281.
17. Moolten F L, Wells J M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 82:1990;297-300.
18. Kwong Y L, Chen S H, Kosai K, Finegold M J, Woo S LC. Adenoviral-mediated suicide gene therapy for hepatic metastasis of breast cancer. Cancer Gene Ther. 3:1996;339-344.
19. Qian C, Bilbao R, Bruna O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology. 22:1995;118-123.
20. Barba D, Hardin J, Sadelain M. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 91:1994;4348-4352.
21. Culver K W, Ram Z, Walbridge S. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550-1552.
22. Samejima Y, Meruelo D. Bystander killing induces apoptosis and is inhibited by forskolin. Gene Ther. 2:1995;50-58.
23. Freeman S M, Abboud C N, Whartenby K A, Packman C H, Koeplin D S, Moolten F L, Abraham G N. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53:1994;5274-5283.
24. Freeman S M, Whartenby K A, Freeman J L, Abboud C N, Marrogi A J. In situ use of suicide genes for cancer therapy. Semin Oncol. 23:1996;31-45.
25. Kisaki H, Ohnishi Y, Azuma Y, Mizuno Y, Ohsaka F. 1-β-d-Arabinosylcystosine and 5-azacytidine induce internucleosomal DNA fragmentation and cell death in thymocytes. Immunopharmacology. 25:1993;19-27.
26. Dilber M S, Abedi M R, Christensson B, Björkstrand B, Kidder G M, Naus C C, Gahrton G, Smith C I. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 57:1997;1523-1528.
27. Simpson I, Rose B, Loewenstein W R. Size limit of molecules permeating the junctional membrane channels. Science. 195:1977;294-296.
28. Freeman S M, Ramesh R, Marrogi A J, Jensen A, Abboud C N. In vivo studies on the mechanism of the 'bystander effect'. Cancer Gene Ther. 1:1994;326.